Alveolar osseous defect in rat for cell therapy: preliminary report

Defeito ósseo alveolar em ratos para terapia celular: estudo preliminar

Abstracts

PURPOSE: To study were to reproduce an alveolar bone defect model in Wistar rats to be used for testing the efficacy of stem cell therapies. Additionally, we also aimed to determine the osteogenesis process of this osseous defect in the 1 month period post-surgery. METHODS: The animals were randomly divided into two groups of 7 animals each. A gingivobuccal incision was made, and a bone defect of 28 mm² of area was performed in the alveolar region. Animals were killed at 2 weeks after surgery (n=7) and 4 weeks after surgery (n=7). RESULTS: The average area of the alveolar defect at time point of 2 weeks was 22.27 ± 1.31 mm² and the average area of alveolar defect at time point of 4 weeks was 9.03 ± 1.17 mm². The average amount of bone formation at time point of 2 weeks was 5.73 ± 1.31 mm² and the average amount of bone formation at time point of 4 weeks was 19 ± 1.17 mm². Statistically significant differences between the amount of bone formation at 2 weeks and 4 weeks after surgery were seen (p=0.003). CONCLUSION: The highest rate of ossification occurred mostly from 2 to 4 weeks after surgery. This observation suggests that 4 weeks after the bone defect creation should be a satisfactory timing to assess the potential of bone inductive stem cells to accelerate bone regeneration in Wistar rats.

Alveolar Bone Loss; Tissue Therapy; Rats

OBJETIVO: Reproduzir um novo modelo de defeito ósseo alveolar em ratos Wistar que será utilizado para terapia genética e estudos com células tronco. Adicionalmente, outro objetivo do presente estudo foi determinar o pico de regeneração óssea do defeito criado na região alveolar do modelo experimental. MÉTODOS: Os animais foram aleatoriamente divididos em dois grupos de sete animais. Através de uma incisão gengivobucal foi criado um defeito ósseo medindo 28 mm² de área na região alveolar dos ratos. Os ratos foram sacrificados após duas semanas (n=7) e quatro semanas (n=7) da cirurgia. RESULTADOS: A área média do defeito alveolar após duas semanas de cirurgia foi de 22.27 ± 1.31 mm² e a área média do defeito alveolar após quatro semanas de cirurgia foi de 9.03 ± 1.17 mm². A taxa de formação óssea foi de 5.73 ± 1.31 mm² após duas semanas de cirurgia e de 19 ± 1.17 mm² após quatro semanas de cirurgia. Foi observada diferença estatisticamente significante na taxa de formação óssea entre o grupo dos animais sacrificados com duas e quatro semanas (p=0.003). CONCLUSÃO: Este estudo demonstrou que a maior taxa de regeneração óssea ocorreu no período entre duas e quatro semanas após a cirurgia de criação do defeito ósseo alveolar, portanto esta observação sugere que o período de tempo de quatro semanas será suficiente para avaliar a capacidade de células tronco em regenerar osso em ratos Wistar com defeito ósseo alveolar.

Perda Óssea Alveolar; Terapia Celular; Ratos

2 - ORIGINAL ARTICLE

MODELS, BIOLOGICAL

Alveolar osseous defect in rat for cell therapy. Preliminary report¹

Defeito ósseo alveolar em ratos para terapia celular. Estudo preliminar

Cassio Eduardo Raposo-Amaral^I; Gerson Shigeru Kobayashi^II; Ana Beatriz Almeida^III; Daniela F. Bueno^IV; Fatima Rodrigues de Souza e Freitas^V; Luiz Carlos Vulcano^VI; Maria Rita Passos-Bueno^VII; Nivaldo Alonso^VIII

^IMD, Plastic Surgeon, Institute of Craniofacial and Plastic Surgery, Campinas-SP, Brazil

^IIBiologist, Department of Genetics and Evolution Biology, Institute of Bioscience, USP, São Paulo, Brazil

^IIIPhD, Biologist, Institute of Craniofacial and Plastic Surgery, Campinas-SP, Brazil

^IVPhD, Dentist, Department of Genetics and Evolution Biology, Institute of Bioscience, USP, São Paulo, Brazil

^VPhD, Biologist, Department of Genetics and Evolution Biology, Institute of Bioscience, USP, São Paulo, Brazil

^VIPhD, Full Professor, Veterinary Medicine, State University of São Paulo, Botucatu-SP, Brazil

^VIIPhD, Full Professor, Department of Genetics and Evolution Biology, Institute of Bioscience, USP, São Paulo, Brazil

^VIIIPhD, Associate Professor, Plastic Surgery Division, Department of Surgery, USP, São Paulo, Brazil

^{Correspondence}

ABSTRACT

PURPOSE: To study were to reproduce an alveolar bone defect model in Wistar rats to be used for testing the efficacy of stem cell therapies. Additionally, we also aimed to determine the osteogenesis process of this osseous defect in the 1 month period post-surgery.

METHODS: The animals were randomly divided into two groups of 7 animals each. A gingivobuccal incision was made, and a bone defect of 28 mm² of area was performed in the alveolar region. Animals were killed at 2 weeks after surgery (n=7) and 4 weeks after surgery (n=7).

RESULTS: The average area of the alveolar defect at time point of 2 weeks was 22.27 ± 1.31 mm² and the average area of alveolar defect at time point of 4 weeks was 9.03 ± 1.17 mm². The average amount of bone formation at time point of 2 weeks was 5.73 ± 1.31 mm² and the average amount of bone formation at time point of 4 weeks was 19 ± 1.17 mm². Statistically significant differences between the amount of bone formation at 2 weeks and 4 weeks after surgery were seen (p=0.003).

CONCLUSION: The highest rate of ossification occurred mostly from 2 to 4 weeks after surgery. This observation suggests that 4 weeks after the bone defect creation should be a satisfactory timing to assess the potential of bone inductive stem cells to accelerate bone regeneration in Wistar rats.

Key words: Alveolar Bone Loss. Tissue Therapy. Rats.

RESUMO

OBJETIVO: Reproduzir um novo modelo de defeito ósseo alveolar em ratos Wistar que será utilizado para terapia genética e estudos com células tronco. Adicionalmente, outro objetivo do presente estudo foi determinar o pico de regeneração óssea do defeito criado na região alveolar do modelo experimental.

MÉTODOS: Os animais foram aleatoriamente divididos em dois grupos de sete animais. Através de uma incisão gengivobucal foi criado um defeito ósseo medindo 28 mm² de área na região alveolar dos ratos. Os ratos foram sacrificados após duas semanas (n=7) e quatro semanas (n=7) da cirurgia.

RESULTADOS: A área média do defeito alveolar após duas semanas de cirurgia foi de 22.27 ± 1.31 mm² e a área média do defeito alveolar após quatro semanas de cirurgia foi de 9.03 ± 1.17 mm². A taxa de formação óssea foi de 5.73 ± 1.31 mm² após duas semanas de cirurgia e de 19 ± 1.17 mm² após quatro semanas de cirurgia. Foi observada diferença estatisticamente significante na taxa de formação óssea entre o grupo dos animais sacrificados com duas e quatro semanas (p=0.003).

CONCLUSÃO: Este estudo demonstrou que a maior taxa de regeneração óssea ocorreu no período entre duas e quatro semanas após a cirurgia de criação do defeito ósseo alveolar, portanto esta observação sugere que o período de tempo de quatro semanas será suficiente para avaliar a capacidade de células tronco em regenerar osso em ratos Wistar com defeito ósseo alveolar.

Descritores: Perda Óssea Alveolar. Terapia Celular. Ratos.

Introduction

Cleft lip and palate (CLP) represent one of the most common congenital human malformations, corresponding to nearly 1/3 of all birth defects. They are very heterogeneous and etiologically complex. The phenotype can vary from simple lip scar or a cleft lip to a complex craniofacial pattern involving the palate, maxilla, zygoma, orbit and cranium. The incidence of the different forms vary: cleft lip with or without cleft palate (CLP) is the most frequent (~1:1000 live births) while craniofacial clefts are quite rare, with an estimate incidence of 1.43 to 4.84 per 100 000 live births^1-3.

Surgical correction of CLP cleft can be challenging. Strategies for closing the bone defect include autologous bone grafts and soft tissue repair with local flaps⁴. An adequate bone stock in the cleft region is required to establish continuity of the craniofacial skeleton. In addition, satisfactory bone stock in the cleft region is required to facilitate tooth eruption and the closure of oronasal fistulas^5-10. Older patients with cleft lip and/or cleft palate may experience slow wound healing, bone graft absorption or recurrent fistulas, resulting in failed tooth eruption¹¹. Early treatment may avoid an unsatisfactory outcome.

An alternative promising technique to enhance bone regeneration in patients with CLP involves the use of tissue-engineered bone, which involves stem cells of various sources with osteogenic potential placed within a biocompatible scaffold^7,12,13.

An appropriate animal model is essential for testing tissue-engineered bone and new strategies for healing bone defects^12,14-16. Alveolar maxillary bone defects have been described in primate, ovine and canine models^17-20, however, the use of large animals is expensive and requires a specific setting.

Rodent models have been used in the majority of studies, investigating new bone-inductive agents^13-16,21,22. Mehrara et al.¹⁵ created a rat model of gingivoperiosteoplasty in which a bone defect in the palatal bone was produced¹⁵. However, the lack of soft tissue coverage of rat palatal bone may be a limitation of this model with regard to the development of three dimensional biocompatible scaffolds seeded with cells for bone regeneration. Nguyen et al.²³ recently established a critical-sized alveolar defect in rats and determined by means of micro-computed tomography and histology the ratio of ossification at 4, 8 and 12 weeks after surgery. They did not observe statistically significant difference in bone formation among 4, 8 and 12 weeks, suggesting that 4 weeks would be a plateau of bone formation.

The purposes of the present study were to reproduce an alveolar bone defect model in Wistar rats to be used for testing the efficacy of stem cell therapies as well as to determine the rate of bone formation of this osseous defect within the first month post-surgery.

Methods

All experiments were performed in accordance with the guidelines set by the Standing Committee on Animal Research of the Institute of Bioscience, University of São Paulo. Adult male, 4-months-old, Wistar-rats, weighing 350g to 500g, were housed individually in a temperature-, light-,and humidity- controlled environment. Animals were fed a standard diet preoperatively. Postoperatively, animals were fed a soft diet for 1 week, after which the normal diet was re-established.

Surgical procedure

Animals were anesthetized with an intraperitoneal injection (0.3 mL/100 g body weight) of ketamine hydrochloride (5%) combined with xylazine (2%). Rats were placed in a lateral position for the surgical procedure. Lidocaine with adrenaline, (0.3 mL) was used for anesthesia of the oral mucosa. A 1.5-cm incision was made in the transitional zone of dry to wet oral mucosa. A tongue traction maneuver was performed to keep the airway open during the surgical procedure. The underlying muscle and maxillary periosteum were elevated. The maxilla and zygomatic bone were completely undermined. A fabricated methyl methacrylate rectangular mold was used to produce a standardized bone defect of 28 mm² of area (7 mm anteroposterior, 4 mm mediolateral and, 2 mm deep). A caliper was used to measure the bone defect. A high-speed burr with constant irrigation was used to create the bone defect. One rat aspirated water during surgery and died. This animal was replaced. Otherwise, all 14 rats tolerated the surgical procedure well. They were fed a standard soft diet for 1 week after surgery and seemed to eat without problem; average weight loss at 4 weeks was 25 g, corresponding to a 6% to 7 % loss of body weight. Animals were killed at 2 and 4 weeks (n=7 per time point) by carbon dioxide narcosis. The size of bone defect as well as measurement of bone formation at each time point were performed and compared (Figures 1 and 2).

Histologic preparation

Samples of the alveolar bone defect were prepared for histologic analysis. The studied tissue samples were fixed in 10% formalin for 24 hours, decalcified in 5 % formic acid for 48 hours, and paraffin-embedded. Sections measuring 5 µm were stained with hematoxylin and eosin and examined under a light microscope.

Radiographic analysis

Rats craniofacial skeleton were imaged immediately after surgery and postoperatively at 2 weeks (n=7) and 4 weeks (n=7) by computerized tomography. Scans were reconstructed as tree-dimensional isosurfaces using InVesalius biomedical software (DT3D-CTI-Brazil). Each tree-dimensional imaging was evaluated at a critical threshold toll, with the densest intensity interpreted as bone. The area of the bone defect was measured on a tree-dimensional images using Magics 13.0 (Materialise-Belgic, software CAD) at O, 2 and 4 weeks.

Measurement of bone formation

The amount of bone formation was measured by calculating the difference between the initial size of bone defect from the size of the bone defect at 4 weeks and 2 weeks after surgery.

Statistical analysis

The amount of bone formation at 2 weeks and 4 weeks after surgery were compared using a Mann-Whitney test. All data were expressed as mean± SEM. A value of p<0.05 was considered to be statistically significant.

Results

The average area of the alveolar defect at 2 weeks after surgery was 22.27 ± 1.31 mm² and the average area of alveolar defect at 4 weeks after surgery was 9.03 ± 1.17 mm². The average amount of bone formation at time point of 2 weeks was 5.73 ± 1.31 mm² and the average amount of bone formation at time point of 4 weeks was 19 ± 1.17 mm². Statistically significant differences between the amount of bone formation at 2 weeks and 4 weeks after surgery was seen (p=0.003). Our study showed that the highest rate of ossification occurred mostly from 2 to 4 weeks, being more than two times higher at 4weeks period in comparison of 2 weeks period (Figure 3).

Histologically, intense osteoblast activities with polymorphonuclear cells as well as woven bone layer was seen Figures 4 and 5).

Discussion

Currently, CLP teams are focused to decrease the number of operations of their children during the process of rehabilitation. Attempts of early bone grafting with rib has brought several complications as well as high morbidity of donor sites²³.

Gingivoperiosteoplasty (GPP) was an alternative technique described in 1965 that aimed to regenerate bone on the alveolar defect, without the potential complication of having a donor site at early age²⁴. However, studies have described variable rates of success of bone regeneration on the alveolar defects and long term complications on facial growth^25,26.

Tissue engineering studies have identified alternative methods that may allow early rehabilitation and decreased average number of operations until adult age. Bone morphegenic protein (BMP-2) was used to reconstruct cranial defects²⁷. Alonso et al.²⁹ have demonstrated in a clinical study that the reossification occurred in different distribution pattern and more slowly in the group of BMP in comparison with the group of iliac crest bone graft, that remains as gold standard therapy for alveolar cleft repair²⁸. The potential of bone formation after placement of BMP was also showed in animal models with cranial defects²⁹. Interestingly, BMP did not cause immunologic reaction after its use in a rat model. Stem cells with osteogenic potential has been another alternative, that may be used in further clinical trials to promote early rehabilitation of children with cleft lip and palate. Bone marrow stem cells seeded onto a resorbable sponge with satisfactory bone healing outcomes has shown several advantages regarding to donor site morbidity⁷. Ideally, patients would be benefited with autologous sources of stem cells, however it may not be promptly available. A novel source of osteogenic stem cell were isolated from the lip muscle of children born with CLP. Small fragments of lip muscle are commonly discarded after primary surgery of cleft lip repair at 3 months of age³⁰. Bone inductive stem cells could be included in the alveolar pocket of patients with CLP at the time of palate repair, promoting bony growth and consequently early rehabilitation. Alternatively, a stem cells bank would lead widespread use for early rehabilitation of the growing population of cleft children. However, several issues need to be addressed before its use in clinical trials, such as; 1- amount of stem cells needed to regenerate sufficient bone in the alveolar gap. 2- The possibility of using heterologous sources of stem cells from stem cells bank. 3- Quality and amount of bone formed in the alveolar gap. For this reason an animal model, that allows some answers prior to clinical trials is primordial. In the present study, we reproduced an osseous defect in the maxillary alveolar region of Wistar rats. The present report confirms that after one month post-surgery the original defect of 28 mm² was still not healed. We also observed that the highest rate of ossification occurred mostly from 2 to 4 weeks. Histologically, osteoblast activities and polymorphonuclear cells as well as woven bone layers are seen, suggesting intense osteogenesis phenomenon, however, this process does not seem enough to totally regenerate the bone defect. Considering that a plateau of bone formation starting at 4 weeks after surgery was previously demonstrated³¹, we suggest that evaluation at 4 weeks after the bone defect creation should be a satisfactory timing to assess the potential of bone inductive stem cells to accelerate bone regeneration in Wistar rats.

The model presented herein is an alveolar osseous defect, that is, on the other hand, reproducible and feasible, that simulates the tridimensional osseous defect in cleft lip/palate patients. Traditionally, bone calvarial defects are being used to study bone inductive agents, however satisfactory results achieved in the cranial bone would not be replicable to alveolar and maxillary bone, because of the role of dura mater and pericranium on the bone formation. This is a preliminary report constructed for further cell therapy testing. Results of this study suggests that 4 weeks after the bone defect creation should be a satisfactory timing to assess the potential of bone inductive agents, including stem cells to accelerate bone regeneration and answer the queries previously raised. Our results suggested that most of the osteogenesis phenomenon occurred from 0 to 4 weeks in this animal model. In summary, this model will allow studies with tissue-engineered bone associated with stem cells in order to evaluate the effectiveness of strategies to speed up the healing process of CLP alveolar defects, leading to early rehabilitation of these children.

Conclusion

Our study showed that the highest rate of ossification occurred mostly from 2 to 4 weeks after the alveolar bone defect creation. This observation together with the data on the literature suggests that 4 weeks after the bone defect creation should be a satisfactory timing to assess the potential of bone inductive stem cells to accelerate bone regeneration in Wistar rats.

Received: January 18, 2010

Review: March 15, 2010

Accepted: April 19, 2010

Conflict of interest: none

Financial source: FAPESP, CNPq, CEPID

1 Research performed at Department of Genetics and Evolution Biology, Institute of Biosciences, University of São Paulo (USP), Brazil.

• 1.Gonzalez BS, Lopez ML, Rico MA, Garduno F. Oral clefts: a retrospective study of prevalence and predisposal factors in the State of Mexico. J Oral Sci. 2008;50(2):123-9.
• 2.Kawamoto HK, Jr. The kaleidoscopic world of rare craniofacial clefts: order out of chaos (Tessier classification). Clin Plast Surg. 1976;3(4):529-72.
• 3.Aqrabawi HE. Facial cleft and associated anomalies: incidence among infants at a Jordanian medical centre. East Mediterr Health J. 2008;14(2):356-9.
• 4.Monasterio FO, Taylor JA. Major craniofacial clefts: case series and treatment philosophy. Plast Reconstr Surg. 2008;122(2):534-43.
• 5.Chen KT, Huang CS, Noordhoff SM. Alveolar bone grafting in unilateral complete cleft lip and palate patients. Changgeng Yi Xue Za Zhi. 1994;17(3):226-34.
• 6.Feichtinger M, Mossbock R, Karcher H. Evaluation of bone volume following bone grafting in patients with unilateral clefts of lip, alveolus and palate using a CT-guided three-dimensional navigation system. J Craniomaxillofac Surg. 2006;34(3):144-9.
• 7.Gimbel M, Ashley RK, Sisodia M, Gabbay JS, Wasson KL, Heller J, Wilson L, Kawamoto HK, Bradley JP. Repair of alveolar cleft defects: reduced morbidity with bone marrow stem cells in a resorbable matrix. J Craniofac Surg. 2007;18(4):895-901.
• 8.Rullo R, Festa VM, Guida L, Laino G. Bone grafting with platelet-rich plasma in alveolar cleft. Case report. Minerva Stomatol. 2007;56(1-2):63-71.
• 9.Siciliano S, Savastano G, Reychler H. The role of autologous parietal bone graft in alveolar cleft. Minerva Stomatol. 1995;44(9):389-95.
• 10.Troxell JB, Fonseca RJ, Osbon DB. A retrospective study of alveolar cleft grafting. J Oral Maxillofac Surg. 1982;40(11):721-5.
• 11.Dickinson BP, Ashley RK, Wasson KL, O'Hara C, Gabbay J, Heller JB, Bradley JP. Reduced morbidity and improved healing with bone morphogenic protein-2 in older patients with alveolar cleft defects. Plast Reconstr Surg. 2008;121(1):209-17.
• 12.Kawata T, Kohno S, Fujita T, Sugiyama H, Tokimasa C, Kaku M, Tanne K. New biomaterials and methods for craniofacial bone defect: chondroid bone grafts in maxillary alveolar clefts. J Craniofac Genet Dev Biol. 2000;20(1):49-52.
• 13.de Mendonca Costa A, Bueno DF, Martins MT, Kerkis I, Kerkis A, Fanganiello RD, Cerruti H, Alonso N, Passos-Bueno MR. Reconstruction of large cranial defects in nonimmunosuppressed experimental design with human dental pulp stem cells. J Craniofac Surg. 2008;19(1):204-10.
• 14.el-Bokle D, Smith SJ, Germane N, Sharawy M. New technique for creating permanent experimental alveolar clefts in a rabbit model. Cleft Palate Craniofac J. 1993;30(6):542-7.
• 15.Mehrara BJ, Saadeh PB, Steinbrech DS, Dudziak M, Grayson BH, Cutting CB, McCarthy JG, Gittes GK, Longaker MT. A rat model of gingivoperiosteoplasty. J Craniofac Surg. 2000;11(1):54-8.
• 16.Takano-Yamamoto T, Kawakami M, Sakuda M. Defects of the rat premaxilla as a model of alveolar clefts for testing bone-inductive agents. J Oral Maxillofac Surg. 1993;51(8):887-91.
• 17.Ehler WJ, Marx RE, Cissik JH, Hubbard GB. Simulated nasoalveolar palatal defects: a canine model to study bone grafts. J Invest Surg. 1990;3(4):341-7.
• 18.El-Deeb M, Horswell B, Waite DE. A primate model for producing experimental alveolar cleft defects. J Oral Maxillofac Surg. 1985;43(7):523-7.
• 19.Papadopulos NA, Papadopoulos MA, Zeilhofer HF, Boos H, Henke J, Erhardt W, Boettcher P, Stolla R, Kovacs L, Biemer E. Intrauterine autogenous foetal bone transplantation for the repair of cleft-like defects in the mid-gestational sheep model. J Craniomaxillofac Surg. 2004;32(4):199-210.
• 20.Wenghoefer MH, Deprest J, Goetz W, Kuijpers-Jagtman AM, Berge S. Prenatal cleft lip and maxillary alveolar defect repair in a 2-step fetal lamb model. J Oral Maxillofac Surg. 2007;65(12):2479-86.
• 21.Gupta DM, Kwan MD, Slater BJ, Wan DC, Longaker MT. Applications of an athymic nude mouse model of nonhealing critical-sized calvarial defects. J Craniofac Surg. 2008;19(1):192-7.
• 22.Pinholt EM, Bang G, Haanaes HR. Alveolar ridge augmentation by osteoinduction in rats. Scand J Dent Res. 1990;98(5):434-41.
• 23.Nguyen PD, Lin CD, Allori AC, Ricci JL, Saadeh PB, Warren SM. Establishment of a critical-sized alveolar defect in the rat: a model for human gingivoperiosteoplasty. Plast Reconstr Surg. 2009;123(3):817-25.
• 24.Robinson F, Wood B. Primary bone grafting in the treatment of cleft lip and palate with special reference to alveolar collapse. Br J Plast Surg. 1969;22(4):336-42.
• 25.Skoog T. The use of periosteal flaps in the repair of clefts of the primary palate. Cleft Palate J. 1965;2:332-9.
• 26.Sato Y, Grayson BH, Garfinkle JS, Barillas I, Maki K, Cutting CB. Success rate of gingivoperiosteoplasty with and without secondary bone grafts compared with secondary alveolar bone grafts alone. Plast Reconstr Surg. 2008;121(4):1356-67; discussion 1368-9.
• 27.Matic DB, Power SM. Evaluating the success of gingivoperiosteoplasty versus secondary bone grafting in patients with unilateral clefts. Plast Reconstr Surg. 2008;121(4):1343-53; discussion 1368-9.
• 28.Docherty Skogh AC, Engstrand T. Bone morphogenetic proteins in cranial reconstructions: clinical evaluation of heparin-chitosan as a carrier for BMP-2. Plast Reconstr Surg. 2009;123(6):192e-3e.
• 29.Alonso N,Tanikawa DYS,Rocha DL,da Silva Freitas R,Canan LW,Jr,Ozawa TO.Preliminary results of maxillary alveolar cleft repair using recombinant human bone morphogenetic protein-2.International proceedings of 11^th international congress on cleft lip and palate and related craniofacial anomalies. Bologna: Medimond; 2009. p.1-4.
• 30.Hyun SJ, Han DK, Choi SH, Chai JK, Cho KS, Kim CK, Kim CS. Effect of recombinant human bone morphogenetic protein-2, -4, and -7 on bone formation in rat calvarial defects. J Periodontol. 2005;76(10):1667-74.
• 31.Bueno DF, Kerkis I, Costa AM, Martins MT, Kobayashi GS, Zucconi E, Fanganiello RD, Salles FT, Almeida AB, do Amaral CE, Alonso N, Passos-Bueno MR. New source of muscle-derived stem cells with potential for alveolar bone reconstruction in cleft lip and/or palate patients. Tissue Eng. Part A. 2009;15(2):427-35.

Publication Dates

• Publication in this collection
  26 July 2010
• Date of issue
  Aug 2010

History

• Accepted
  19 Apr 2010
• Reviewed
  15 Mar 2010
• Received
  18 Jan 2010